Clinical trials: Newly Diagnosed Glioblastoma, IDH-wildtype
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma
Background: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months.
- Trial name
- NCT06419946
- Testing
- Temozolomide, Lomustine
- Where
- 20 sites in Austria, Denmark and 2 more
- Volunteers
- 200 people
- Sponsor
- Vastra Gotaland Region
Primary Glioblastoma
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
This is a multi-center, double-blind, 2:1 randomized phase III trial to determine whether the addition of AV-GBM-1, a therapeutic, patient-specific dendritic cell vaccine, to standard therapy increases OS of patients with a…
- Trial name
- NCT05100641
- Testing
- AV-GBM-1, Autologous monocytes
- Volunteers
- 672 people
- Sponsor
- Aivita Biomedical, Inc.
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Niacin in Glioblastoma
This is a single institution Phase I-II study to evaluate the tolerability and Maximum Tolerated Dose (MTD) (Phase I) and efficacy (Phase II) of adding Niacin CRT™ to standard first line treatment (concurrent Radiation Therapy…
- Trial name
- NCT04677049
- Testing
- Niacin CRT
- Where
- Canada
- Volunteers
- 59 people
- Sponsor
- AHS Cancer Control Alberta
Newly Diagnosed Glioblastoma, IDH-wildtype
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
This is an investigator-initiated, randomized, open-label, parallel-controlled clinical study designed to evaluate the efficacy and safety of locally administered Tris-CAR-T cells in adults with newly diagnosed glioblastoma.
- Trial name
- CAR-T (NCT07873996)
- Testing
- Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma, IDH-wildtype
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an…
- Trial name
- NCT06359379
- Testing
- Ropidoxuridine
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Shuttle Pharmaceuticals, Inc.
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
This study will evaluate the addition of regorafenib to standard of care treatment with TMZ as adjuvant therapy, and in combination with TMZ+RT as concomitant therapy.
- Trial name
- REGOMA-2 (NCT06095375)
- Testing
- Regorafenib, Temozolomide
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Glioblastoma, IDH-wildtype
Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma
The goal of this phase II randomized clinical trial is to compare the safety and efficacy of Elemene plus Stupp Protocol (the new protocol) and Stupp Protocol alone (the standard protocol) in patients with newly-diagnosed…
- Trial name
- NCT05842746
- Testing
- Elemene
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Peking Union Medical College Hospital
Malignant Glioma of Brain
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ).
- Trial name
- NCT03011671
- Testing
- Acetazolamide, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Glioblastoma
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2…
- Trial name
- NOVA-GBM (NCT07604285)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Glioblastoma
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed…
- Trial name
- GBM AGILE (NCT03970447)
- Testing
- Temozolomide, Lomustine, Regorafenib
- Where
- 63 sites in United States, Australia and 4 more
- Volunteers
- 2,250 people
- Sponsor
- Global Coalition for Adaptive Research
Glioblastoma (GBM)
A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients
The purpose of the study is to determine the recommended dose and further understand the safety of MT-125 in participants who have been diagnosed with glioblastoma, a primary brain tumor, when administered in combination with…
- Trial name
- STAR-GBM (NCT07185880)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma WHO Grade IV
Phase 0 With Expansion Phase Clinical Trial of Quisinostat Plus Radiotherapy in Newly-diagnosed and Recurrent Grade 4 IDH-Wildtype Glioblastomas
This is an open-label, multi-center Phase 0/1b study that will enroll up to 18 participants with recurrent WHO grade 4 glioblastoma (rGBM) IDH-wildtype (IDH-WT), Arm A, and 12 participants with presumed newly-diagnosed WHO grade…
- Trial name
- NCT06824662
- Testing
- Quisinostat
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Nader Sanai
Glioblastoma, Malignant Glioma
Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
- Trial name
- NCT02047058
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents drugs carried in the bloodstream from getting into the brain.
- Conditions
- Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
- Trial name
- NCT05864534
- Testing
- Balstilimab, Botensilimab, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
The primary purpose of the Phase 1 (Dose Escalation) of this study is to identify the dose-limiting toxicities (DLTs) of zedoresertib combined with temozolomide (TMZ) (Arm A) and with TMZ and radiotherapy (RT) (Arms B and C) and…
- Trial name
- NCT05765812
- Testing
- Zedoresertib, Temozolomide, Radiotherapy
- Where
- 16 sites in United States, Spain and 1 more
- Volunteers
- 116 people
- Sponsor
- Debiopharm International SA
Brain and Central Nervous System Tumors
Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Motexafin gadolinium may increase the effectiveness of radiation therapy by making tumor cells more sensitive to radiation.
- Trial name
- NCT00003409
- Testing
- motexafin gadolinium, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma.
- Trial name
- NCT05879250
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Northwestern University
Glioblastoma, IDH Wild-type and STAT3-positive Glioblastoma
Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients
Multicenter, double-blind, placebo-controlled, randomized trial. Patients affected by STAT3 positive newly diagnosed glioblastoma will be eligible.
- Trial name
- STRONG (NCT06964815)
- Testing
- Silibinin as STAT3 inhibitor
- Where
- 16 sites in Italy
- Sponsor
- Istituto Oncologico Veneto IRCCS